Literature DB >> 10898700

In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188.

S Espuelas1, P Legrand, P M Loiseau, C Bories, G Barratt, J M Irache.   

Abstract

A micellar formulation of amphotericin B (AmB) solubilized with poloxamer 188 was evaluated against an AmB Leishmania donovani-resistant line. A concave isobologram showed a synergistic effect of this association against promastigotes. This result was confirmed with amastigotes since the 50% effective concentration of the new formulation was 100 times less than that of the control AmB formulation.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898700      PMCID： PMC90038          DOI： 10.1128/AAC.44.8.2190-2192.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

Authors:  A Meyerhoff
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

Review 2.  Soluble self-assembled block copolymers for drug delivery.

Authors:  G S Kwon; T Okano
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

3.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 5.  Use of nonionic block copolymers in vaccines and therapeutics.

Authors:  M J Newman; J K Actor; M Balusubramanian; C Jagannath
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1998       Impact factor: 4.889

Review 6.  Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.

Authors:  J Berman; R Dietze
Journal:  Chemotherapy       Date:  1999-06       Impact factor: 2.544

Review 7.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

Review 8.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

9.  Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis.

Authors:  A B Mullen; K C Carter; A J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

10.  Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

Authors:  N Mbongo; P M Loiseau; M A Billion; M Robert-Gero
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191
View more
  9 in total

1.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

2.  Design and antileishmanial activity of amphotericin B-loaded stable ionic amphiphile biovector formulations.

Authors:  P M Loiseau; L Imbertie; C Bories; D Betbeder; I De Miguel
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms.

Authors:  Christopher Fernandez-Prada; Isabel M Vincent; Marie-Christine Brotherton; Mathew Roberts; Gaétan Roy; Luis Rivas; Philippe Leprohon; Terry K Smith; Marc Ouellette
Journal:  PLoS Negl Trop Dis       Date:  2016-12-02

5.  Physico-Chemical Characterization and Biopharmaceutical Evaluation of Lipid-Poloxamer-Based Organogels for Curcumin Skin Delivery.

Authors:  Aryane Alves Vigato; Samyr Machado Querobino; Naially Cardoso de Faria; Ana Carolina Bolela Bovo Candido; Lizandra Guidi Magalhães; Cíntia Maria Saia Cereda; Giovana Radomille Tófoli; Estefânia Vangelie Ramos Campos; Ian Pompermayer Machado; Leonardo Fernandes Fraceto; Mirela Inês de Sairre; Daniele Ribeiro de Araujo
Journal:  Front Pharmacol       Date:  2019-09-12       Impact factor: 5.810

6.  Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.

Authors:  Rafaella R Costa; João A Oliveira-da-Silva; Thiago A R Reis; Grasiele S V Tavares; Débora V C Mendonça; Camila S Freitas; Daniela P Lage; Vívian T Martins; Luciana M R Antinarelli; Amanda S Machado; Raquel S Bandeira; Fernanda Ludolf; Thaís T O Santos; Rory C F Brito; Maria V Humbert; Daniel Menezes-Souza; Mariana C Duarte; Miguel A Chávez-Fumagalli; Bruno M Roatt; Elaine S Coimbra; Eduardo A F Coelho
Journal:  Med Microbiol Immunol       Date:  2021-04-18       Impact factor: 3.402

7.  In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis.

Authors:  Camila S Freitas; Daniela P Lage; João A Oliveira-da-Silva; Rafaella R Costa; Débora V C Mendonça; Vívian T Martins; Thiago A R Reis; Luciana M R Antinarelli; Amanda S Machado; Grasiele S V Tavares; Fernanda F Ramos; Rory C F Brito; Fernanda Ludolf; Miguel A Chávez-Fumagalli; Bruno M Roatt; Gabriela S Ramos; Jennifer Munkert; Flaviano M Ottoni; Priscilla R V Campana; Mariana C Duarte; Denise U Gonçalves; Elaine S Coimbra; Fernão C Braga; Rodrigo M Pádua; Eduardo A F Coelho
Journal:  Parasite       Date:  2021-04-14       Impact factor: 3.000

Review 8.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

9.  Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia.

Authors:  Carlos Franco-Muñoz; Merab Manjarrés-Estremor; Clemencia Ovalle-Bracho
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.